What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Alzheimer's disease
The scientist’s investigation covers issues in Internal medicine, Cerebrospinal fluid, Pathology, Neurology and Dementia.
His work deals with themes such as Endocrinology and Oncology, which intersect with Internal medicine.
The various areas that he examines in his Cerebrospinal fluid study include Amyloid beta, Hyperintensity, Amyloid β peptide and Mass spectrometry.
His Pathology research incorporates elements of Biomarker and Pharmacology.
His studies in Biomarker integrate themes in fields like Immunoassay, Meta-analysis, Disease and Immunology.
His Neurology research is multidisciplinary, incorporating perspectives in Gastroenterology, Mini–Mental State Examination and Vascular dementia.
His most cited work include:
- CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis (784 citations)
- Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders (301 citations)
- The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers (301 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Cerebrospinal fluid, Internal medicine, Pathology, Biomarker and Dementia.
His work in Cerebrospinal fluid tackles topics such as Neurology which are related to areas like Neurodegeneration and Cognition.
His studies deal with areas such as Gastroenterology, Endocrinology and Oncology as well as Internal medicine.
His Pathology research focuses on Gene isoform and how it connects with Pharmacology.
His Biomarker research focuses on Bioinformatics and how it relates to Biomarker discovery.
His Dementia study integrates concerns from other disciplines, such as Apolipoprotein E, Area under the curve and Cohort.
He most often published in these fields:
- Cerebrospinal fluid (70.70%)
- Internal medicine (59.53%)
- Pathology (33.95%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (59.53%)
- Cerebrospinal fluid (70.70%)
- Dementia (30.23%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Cerebrospinal fluid, Dementia, Biomarker and Oncology.
His research integrates issues of Gastroenterology and Neurology in his study of Internal medicine.
His Cerebrospinal fluid research is multidisciplinary, incorporating elements of Extracellular matrix and Endocrinology.
His biological study spans a wide range of topics, including Alzheimer's disease, Neurodegeneration and SNP.
The concepts of his Biomarker study are interwoven with issues in Positron emission tomography, Area under the curve and Pathology.
Ulf Andreasson works mostly in the field of Oncology, limiting it down to concerns involving Neuroimaging and, occasionally, Clinical trial and Peripheral.
Between 2018 and 2021, his most popular works were:
- Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. (157 citations)
- Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. (157 citations)
- Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis (154 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Alzheimer's disease
Ulf Andreasson mainly focuses on Dementia, Internal medicine, Neurology, Neurodegeneration and Cognitive decline.
His Dementia research incorporates themes from Alzheimer's disease and Biomarker.
His study in Internal medicine is interdisciplinary in nature, drawing from both Neuroimaging and Oncology.
He combines subjects such as Cognition, Blood biomarkers and Intensive care medicine with his study of Neurodegeneration.
His Cognitive decline research is multidisciplinary, relying on both Apolipoprotein E, Amyloid beta and Neuroscience.
He works mostly in the field of Clinical trial, limiting it down to topics relating to Alzheimer's Disease Neuroimaging Initiative and, in certain cases, Cerebrospinal fluid.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
